期刊文献+

腹腔热灌注化疗对卵巢癌患者血清miR-200a的影响

Effect of intraperitoneal hyperthermic perfusion chemotherapy on serum miR-200a in patients with ovarian cancer
原文传递
导出
摘要 目的:探讨腹腔热灌注化疗对卵巢癌患者血清miR-200a的影响。方法:将82例手术治疗后的卵巢癌患者随机分为两组,观察组与对照组各41例。观察组采用全身静脉化疗联合腹腔热灌注化疗,对照组采用全身静脉化疗联合普通腹腔灌注化疗。治疗3个疗程后观察疗效,并且测定患者血清miR-200a。结果:观察组总有效率为87.8%,对照组总有效率为73.2%,两组差异有统计学意义(P<0.05)。治疗后两组患者血清miR-200a均有明显降低,观察组降低更加明显(P<0.05)。结论:腹腔热灌注化疗对卵巢癌的效果更明显,可能与减少miR-200a的表达有关系。 Objective: To study the effect of intraperitoneal hyperthermic perfusion chemotherapy on serum miR- 200a in patients with ovarian cancer. Methods: Eight-two patients with ovarian cancer after operation were randomly divided into two groups, the observation group( n = 41 ) and the control group (n = 41 ). The patients in the observation group were treated through intravenous plus intraperitoneal hyperthermic perfusion chemotherapy, while the patients in the control group were treated through intravenous plus intraperitoneal perfusion chemotherapy. They were all treated for three courses. The level of serum miR-200a in two groups was detected. Results: The total efficient rates were 87.8% in the observation group and 73.2% in the control group. There was a significant difference between two groups (P 〈 0.05 ). The level of serum miR-200a in both groups was decreased after chemotherapy and it was lower in the observation group than that in the control group ( P 〈 0.05 ). Conclusion: Hyperthermic perfusion chemotherapy can decrease miR-200a which can improve ovarian cancer.
作者 王丹
出处 《现代医学》 2014年第2期142-145,共4页 Modern Medical Journal
关键词 卵巢癌 热灌注 miR-200a ovarian cancer hyperthermic perfusion miR-200a
  • 相关文献

参考文献12

  • 1NICOLETrO M O, DALLA P M, DONACH M E, et al. Positive experience of intraperitoneal chemotherapy followed by intrave- nous chemotherapy in heavily pretreated paJjents with subopti- mal residual ovarian cancer and primary peritoneal cancer[ J ]. Tumori ,2010,96 (6) :918-925.
  • 2ARMSTRONG D, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[ J]. N Engl J Med, 2006,354 (7) : 34-43.
  • 3李晓翠,严沁,万菁,欧阳婧,万小平.miR-200a在卵巢癌患者血清中的表达及临床意义[J].现代妇产科进展,2012,21(12):953-956. 被引量:6
  • 4YAN T D, BLACK D, SAVADY R, et al. Systematic review on the efficacy of cytoreductive surgery combined with periop- erative intraperitoneal chemotherapy for peritoneal carcinoma- tosis rom colorectal carcinoma [ J ]. J Clin Oncol 2008,24 (24) :4011-4019.
  • 5宋坤,孔北华.卵巢癌腹腔化疗的有关问题[J].现代妇产科进展,2010,19(10):721-724. 被引量:10
  • 6BREE E D, PANAYIOTIS A. Treatment of ovarian cancer u- sing intraperitoneal chemotherapy with taxanes: from laborato- ry dench to bedside [ J ]. Cancer Treat Rev, 2006,32 ( 6 ) : 471-482.
  • 7刘伟,李苏宜.卵巢癌化疗新进展[J].肿瘤基础与临床,2006,19(6):526-528. 被引量:19
  • 8TERENCE C C, GREG R, WINSTON L, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis:systematic review of current results [ J ]. J Cancer Res Clin Oncol, 2009, 135(12) :1637-1645.
  • 9黄耀球,王凯.卵巢癌腹腔温热灌注化疗的应用[J].国际医药卫生导报,2012,18(3):357-358. 被引量:3
  • 10蒋森,赵亚萍,杜云翔.MiR-1在肿瘤中的研究进展[J].东南大学学报(医学版),2012,31(5):648-651. 被引量:5

二级参考文献60

  • 1连利娟.卵巢癌化疗的现况与趋向[J].中华妇产科杂志,1996,31(2):67-70. 被引量:39
  • 2Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer [ J ]. Cancer Treat Rep, 1978,62 : 1-11.
  • 3Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection[ J]. Ann Intern Med, 1982,97:845-851.
  • 4Markman M, Howell SB, Lucas WE, et al. Combination intraperitoneal chemotherapy with cisplatin, cytarzbine, and doxombicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity [ J ]. J Clin Oncol, 1984,2 : 1321-1326.
  • 5Petignat P, duBois A, Bruchim I, et al. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovariancancer [ J ] ? Critical Reviews in Oncology/Hematology ,2007,62 : 137-147.
  • 6Hofstra LS,de Vries EG, Mulder NH, et al. Intraperitoneal chemotherapy in ovarian cancer [ J ]. Cancer Treat Rev, 2000,26:133-143.
  • 7Markman M, Reichman B, Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer[J]. Gynccol Oncol, 1993,50 : 100-104.
  • 8Speyer JL, Sorich J. Intraperitoneal earboplatin : rationale and experience [ J ]. Semin Oncol, 1992,19 : 107-113.
  • 9Kuh HJ, Jang SH, Wientjes MG, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor [ J ]. J Pharmacol Exp Ther, 1999,290 : 871-180.
  • 10Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer [ J ]. Gynecol Oncol, 1994,54 : 338-344.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部